Chondrocalcinosis (calcium pyrophosphate crystal disease): look for a metabolic cause
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Chondrocalcinosis found or confirmed CPPD arthritis: look for causes
Fasting laboratory tests
- Serum calcium
- Serum albumin
- Serum phosphate
- Serum ferritin
- Transferrin saturation (in the morning, fasting)
- Serum magnesium (onset before 55-60, diffuse or polyarticular form, or known cause of hypomagnesaemia)if needednon-French guidelineHypomagnesaemia is a recognised metabolic cause [2,3]; the search for metabolic causes is particularly needed before age 55 or in diffuse polyarticular chondrocalcinosis [4].
- PTH, on the same sample as the serum calcium (if serum calcium raised or high-normal)if neededSerum calcium screens for primary hyperparathyroidism, completed if needed by PTH [1]; after age 55, hyperparathyroidism should be considered in all patients [4].
- Alkaline phosphatase (ALP) (if onset before 60)if needednon-French guidelineA leading American review (N Engl J Med, 2016) recommends, before age 60, looking for all associated metabolic diseases, including hypophosphatasia, due to a functional deficiency of alkaline phosphatase, by measuring alkaline phosphatase among others [5]. The COFER (French College of Rheumatology) says to look routinely for the two main causes, haemochromatosis and primary hyperparathyroidism [1]. Low alkaline phosphatase suggests hypophosphatasia [5].
Also consider
- Raised transferrin saturation? If transferrin saturation is raised, see the page “Haemochromatosis”.
- High serum calcium? If serum calcium is raised, see the page “Hypercalcaemia”.
- Acute attack, fever or raised CRP? Septic arthritis can coexist with pseudogout: see the page Monoarthrite aiguë.
Sources (5)
- Collège français des enseignants en rhumatologie (COFER). Item 198 : Arthropathie microcristalline (section 3, rhumatisme à cristaux de pyrophosphate de calcium). Référentiel en ligne du Collège (lecofer.org), consulté le 11 octobre 2026.
- Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-70.
- Abhishek A, Tedeschi SK, Pascart T, et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann Rheum Dis. 2023;82(10):1248-57.
- Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48(7):711-5.
- Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016;374(26):2575-2584.